Proactive Research analyst Ed Stacey presents his research on MGC Pharmaceuticals (LON:MXC) a biopharma company which develops drugs from plant-based sources, including cannabis.
He tells Presenter Katie Pilbeam there are also non cannabis products which could be the real big value drivers in the next 12 months. Ed also explains how the firms’ cannabis extracts for the medical cannabis market, the biggest for them is Australia, are growing fast.
MGC has various clinical trials and development programmes currently underway and two of them that are quite far advanced proprietary formulations from cannabis targeting drug resistant epilepsy and targeting symptoms related to dementia. Stacey says these are both in phase two trials.
Click here to read Proactive analyst Ed Stacey's Initiation Report on MGC Pharmaceuticals